Seeking Alpha

WYE Transcripts Search Results

Results 1-8 for bapineuzumab (out of 8)
Refine your search:

You can use: AND, NOT, OR, " " (exact phrase)

Search across all Transcripts:

You can use: AND, NOT, OR, " " (exact phrase)


  • Wyeth Q2 2009 Earnings Call Transcript 23 Jul, 2009
    ... , and we look forward to advancing the development of bapineuzumab and other assets of the program. So, as we ... any thoughts there. And then just one question on bapineuzumab: Can we just get an update on the enrollment ...
  • Wyeth Q1 2009 Earnings Call Transcript 29 Apr, 2009
    ... the phase three APOE for non-carrier studies with Bapineuzumab to discontinue the highest two milligram per ... our discussions with international regulatory bodies on Bapineuzumab we’ve completed a comprehensive series of ...
  • Wyeth Q3 2008 Earnings Conference Call Transcript 22 Oct, 2008
    ... additional contributions from our pipeline products like bapineuzumab, or our pneumococcal B-vaccine and our new ... trial costs including Prevnar 13-valent for adults, bapineuzumab and several new oncology programs. Our ...
  • Wyeth Q2 2008 Earnings Call Transcript 23 Jul, 2008
    ... findings from the Phase II study of bapineuzumab in patients with mild-to-moderate Alzheimer's disease. As ... 2008 with increasing clinical trial costs including bapineuzumab, PREVNAR 13-valent and a number of oncology ...
  • Wyeth Q1 2008 Earnings Call Transcript 22 Apr, 2008
    ... couple of questions. On the upcoming bapineuzumab data, just hoping you can ... to the NTB endpoint and the bapineuzumab program, you are absolutely correct. ... or has not the Phase III bapineuzumab trail started? I thought it ...
  • Wyeth Q4 2007 Earnings Call Transcript 31 Jan, 2008
    ... pipeline products later. Also further on the horizon, our potential new products like Prevnar 13-valent and bapineuzumab in Alzheimer's. We will continue to advance our pipeline in the increasingly difficult regulatory ...
  • Wyeth Q3 2007 Earnings Call Transcript 18 Oct, 2007
    ... expectations for timing of the release of at least top line data on the Alzheimer's program with bapineuzumab (AAB-001)? Second, can you update us on your expectations for timing of a Markman ruling from the Effexor XR ...
  • Wyeth Q2 2007 Earnings Call Transcript 19 Jul, 2007
    ... of the Phase III program for bapineuzumab or AB-001 in Alzheimer's disease. ... on which other product besides bapineuzumab that we expect to start ... , regarding your inquiry on the bapineuzumab interim analysis of the Phase 2 ...
Search WYE Transcripts:

You can use: AND, NOT, OR, " " (exact phrase)

Most Popular Searches

in WYE transcripts

Other Transcripts
from the Healthcare Sector
  1. AngioDynamics, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
  2. Prospect Medical Holdings Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
  3. Hansen Medical, Inc. Q3 2009 Earnings Call Transcript
To search across transcripts, find the most recent and most popular and view by sector, try: Seeking Alpha's Transcript Center